{"entity":{"type":"insider","cik":"0001413378","url":"/insider/0001413378","json_url":"/insider/0001413378.json","name":"Viking Global Equities II LP","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":64,"n_filings":24,"first":"2014-10-06","last":"2024-06-18","span_basis":"filed_date"},"name_variants":[{"name":"Viking Global Equities II LP","source":"filing","n_filings":24,"first_seen":"2014-10-06","last_seen":"2024-06-18"}],"transactions":[{"id":3150004,"accession":"0000905148-24-001732","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000905148-24-001732","line_url":"/filing/0000905148-24-001732#line-2","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"APi Group Corp","issuer_ticker":"APG","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL INVESTORS LP; VIKING GLOBAL PERFORMANCE LLC; Viking Global Equities II LP; Viking Global Equities Master Ltd.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1912750.0,"shares_display":"1,912,750","price_per_share":38.15,"price_display":"38.15","price_state":"stated","total_value":72971412.5,"total_display":"72,971,412.50","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-06-17","filed_date":"2024-06-18","scope":"insider"},{"id":3150002,"accession":"0000905148-24-001732","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000905148-24-001732","line_url":"/filing/0000905148-24-001732#line-1","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"APi Group Corp","issuer_ticker":"APG","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL INVESTORS LP; VIKING GLOBAL PERFORMANCE LLC; Viking Global Equities II LP; Viking Global Equities Master Ltd.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":39032.0,"shares_display":"39,032","price_per_share":38.15,"price_display":"38.15","price_state":"stated","total_value":1489070.8,"total_display":"1,489,070.80","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-06-17","filed_date":"2024-06-18","scope":"insider"},{"id":2621902,"accession":"0000905148-24-000919","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000905148-24-000919","line_url":"/filing/0000905148-24-000919#line-2","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"APi Group Corp","issuer_ticker":"APG","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL INVESTORS LP; VIKING GLOBAL PERFORMANCE LLC; Viking Global Equities II LP; Viking Global Equities Master Ltd.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2977845.0,"shares_display":"2,977,845","price_per_share":34.25,"price_display":"34.25","price_state":"stated","total_value":101991191.25,"total_display":"101,991,191.25","shares_owned_after":1912750.0,"shares_owned_after_display":"1,912,750","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-05","filed_date":"2024-03-07","scope":"insider"},{"id":2621896,"accession":"0000905148-24-000919","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000905148-24-000919","line_url":"/filing/0000905148-24-000919#line-1","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"APi Group Corp","issuer_ticker":"APG","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL INVESTORS LP; VIKING GLOBAL PERFORMANCE LLC; Viking Global Equities II LP; Viking Global Equities Master Ltd.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":60772.0,"shares_display":"60,772","price_per_share":34.25,"price_display":"34.25","price_state":"stated","total_value":2081441.0,"total_display":"2,081,441.00","shares_owned_after":39032.0,"shares_owned_after_display":"39,032","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-05","filed_date":"2024-03-07","scope":"insider"},{"id":2621854,"accession":"0000905148-24-000079","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000905148-24-000079","line_url":"/filing/0000905148-24-000079#line-3","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"APi Group Corp","issuer_ticker":"APG","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL INVESTORS LP; VIKING GLOBAL PERFORMANCE LLC; Viking Global Equities II LP; Viking Global Equities Master Ltd.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6300817.0,"shares_display":"6,300,817","price_per_share":31.3,"price_display":"31.30","price_state":"stated","total_value":197215572.1,"total_display":"197,215,572.10","shares_owned_after":27032516.0,"shares_owned_after_display":"27,032,516","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-01-02","filed_date":"2024-01-04","scope":"insider"},{"id":2621849,"accession":"0000905148-24-000079","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000905148-24-000079","line_url":"/filing/0000905148-24-000079#line-2","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"APi Group Corp","issuer_ticker":"APG","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL INVESTORS LP; VIKING GLOBAL PERFORMANCE LLC; Viking Global Equities II LP; Viking Global Equities Master Ltd.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":195200.0,"shares_display":"195,200","price_per_share":31.3,"price_display":"31.30","price_state":"stated","total_value":6109760.0,"total_display":"6,109,760.00","shares_owned_after":837472.0,"shares_owned_after_display":"837,472","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-01-02","filed_date":"2024-01-04","scope":"insider"},{"id":2621842,"accession":"0000905148-24-000079","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000905148-24-000079","line_url":"/filing/0000905148-24-000079#line-1","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"APi Group Corp","issuer_ticker":"APG","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL INVESTORS LP; VIKING GLOBAL PERFORMANCE LLC; Viking Global Equities II LP; Viking Global Equities Master Ltd.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3983.0,"shares_display":"3,983","price_per_share":31.3,"price_display":"31.30","price_state":"stated","total_value":124667.9,"total_display":"124,667.90","shares_owned_after":17088.0,"shares_owned_after_display":"17,088","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-01-02","filed_date":"2024-01-04","scope":"insider"},{"id":7993986,"accession":"0001140361-23-031456","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001140361-23-031456","line_url":"/filing/0001140361-23-031456#line-4","is_derivative":false,"issuer_cik":"0001132625","issuer_name":"Roivant Sciences Ltd.","issuer_ticker":"ROIV","issuer_name_source":null,"issuer_url":"/issuer/0001132625","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL PERFORMANCE LLC; Viking Global Equities II LP; Viking Global Equities Master Ltd.; Viking Long Fund GP LLC; Viking Long Fund Master Ltd.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5427043.0,"shares_display":"5,427,043","price_per_share":9.9,"price_display":"9.90","price_state":"stated","total_value":53727725.7,"total_display":"53,727,725.70","shares_owned_after":31409512.0,"shares_owned_after_display":"31,409,512","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-06-22","filed_date":"2023-06-26","scope":"insider"},{"id":7993985,"accession":"0001140361-23-031456","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001140361-23-031456","line_url":"/filing/0001140361-23-031456#line-3","is_derivative":false,"issuer_cik":"0001132625","issuer_name":"Roivant Sciences Ltd.","issuer_ticker":"ROIV","issuer_name_source":null,"issuer_url":"/issuer/0001132625","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL PERFORMANCE LLC; Viking Global Equities II LP; Viking Global Equities Master Ltd.; Viking Long Fund GP LLC; Viking Long Fund Master Ltd.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5236006.0,"shares_display":"5,236,006","price_per_share":9.9,"price_display":"9.90","price_state":"stated","total_value":51836459.4,"total_display":"51,836,459.40","shares_owned_after":30303871.0,"shares_owned_after_display":"30,303,871","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-06-22","filed_date":"2023-06-26","scope":"insider"},{"id":7993984,"accession":"0001140361-23-031456","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-23-031456","line_url":"/filing/0001140361-23-031456#line-2","is_derivative":false,"issuer_cik":"0001132625","issuer_name":"Roivant Sciences Ltd.","issuer_ticker":"ROIV","issuer_name_source":null,"issuer_url":"/issuer/0001132625","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL PERFORMANCE LLC; Viking Global Equities II LP; Viking Global Equities Master Ltd.; Viking Long Fund GP LLC; Viking Long Fund Master Ltd.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2226195.0,"shares_display":"2,226,195","price_per_share":9.9,"price_display":"9.90","price_state":"stated","total_value":22039330.5,"total_display":"22,039,330.50","shares_owned_after":12884307.0,"shares_owned_after_display":"12,884,307","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-06-22","filed_date":"2023-06-26","scope":"insider"},{"id":7993983,"accession":"0001140361-23-031456","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-23-031456","line_url":"/filing/0001140361-23-031456#line-1","is_derivative":false,"issuer_cik":"0001132625","issuer_name":"Roivant Sciences Ltd.","issuer_ticker":"ROIV","issuer_name_source":null,"issuer_url":"/issuer/0001132625","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL PERFORMANCE LLC; Viking Global Equities II LP; Viking Global Equities Master Ltd.; Viking Long Fund GP LLC; Viking Long Fund Master Ltd.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":110756.0,"shares_display":"110,756","price_per_share":9.9,"price_display":"9.90","price_state":"stated","total_value":1096484.4,"total_display":"1,096,484.40","shares_owned_after":641010.0,"shares_owned_after_display":"641,010","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-06-22","filed_date":"2023-06-26","scope":"insider"},{"id":3219884,"accession":"0001387131-20-011164","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001387131-20-011164","line_url":"/filing/0001387131-20-011164#line-1","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"Adaptive Biotechnologies Corp","issuer_ticker":"ADPT","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"VIKING GLOBAL PERFORMANCE LLC; Viking Global Equities Master Ltd.; Shabet Rose Sharon; HALVORSEN OLE ANDREAS; Viking Global Equities II LP; VIKING GLOBAL INVESTORS LP; Ott David C.; Viking Long Fund Master Ltd.; Viking Long Fund GP LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000000.0,"shares_display":"1,000,000","price_per_share":55.65,"price_display":"55.65","price_state":"stated","total_value":55650000.0,"total_display":"55,650,000.00","shares_owned_after":29993708.0,"shares_owned_after_display":"29,993,708","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-14","filed_date":"2020-12-16","scope":"insider"},{"id":3100610,"accession":"0001387131-20-009936","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001387131-20-009936","line_url":"/filing/0001387131-20-009936#line-1","is_derivative":false,"issuer_cik":"0001132625","issuer_name":"Adaptive Biotechnologies Corp","issuer_ticker":"ADPT","issuer_name_source":null,"issuer_url":"/issuer/0001132625","owner_cik":null,"owner_name":"Viking Long Fund Master Ltd.; HALVORSEN OLE ANDREAS; Ott David C.; Viking Global Equities Master Ltd.; Shabet Rose Sharon; Viking Global Equities II LP; VIKING GLOBAL PERFORMANCE LLC; Viking Long Fund GP LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2500000.0,"shares_display":"2,500,000","price_per_share":49.515,"price_display":"49.52","price_state":"stated","total_value":123787500.0,"total_display":"123,787,500.00","shares_owned_after":30993708.0,"shares_owned_after_display":"30,993,708","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-11-11","filed_date":"2020-11-13","scope":"insider"},{"id":3320402,"accession":"0000903423-20-000011","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000903423-20-000011","line_url":"/filing/0000903423-20-000011#line-1","is_derivative":false,"issuer_cik":"0001132625","issuer_name":"Adaptive Biotechnologies Corp","issuer_ticker":"ADPT","issuer_name_source":null,"issuer_url":"/issuer/0001132625","owner_cik":null,"owner_name":"Viking Long Fund GP LLC; Ott David C.; HALVORSEN OLE ANDREAS; Viking Global Equities II LP; VIKING GLOBAL PERFORMANCE LLC; Viking Global Equities Master Ltd.; Viking Long Fund Master Ltd.; Shabet Rose Sharon","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4912899.0,"shares_display":"4,912,899","price_per_share":24.9763,"price_display":"24.98","price_state":"stated","total_value":122706039.2937,"total_display":"122,706,039.29","shares_owned_after":33493708.0,"shares_owned_after_display":"33,493,708","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-01-28","filed_date":"2020-01-30","scope":"insider"},{"id":8665377,"accession":"0000903423-19-000253","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000903423-19-000253","line_url":"/filing/0000903423-19-000253#line-3","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"VIKING GLOBAL PERFORMANCE LLC; Shabet Rose Sharon; HALVORSEN OLE ANDREAS; Ott David C.; Viking Long Fund Master Ltd.; Viking Long Fund GP LLC; Viking Global Equities Master Ltd.; Viking Global Equities LP; VGE III Portfolio Ltd.; Viking Global Equities II LP","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4957.0,"shares_display":"4,957","price_per_share":8.1693,"price_display":"8.17","price_state":"stated","total_value":40495.2201,"total_display":"40,495.22","shares_owned_after":22860013.0,"shares_owned_after_display":"22,860,013","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-19","filed_date":"2019-06-19","scope":"insider"},{"id":8665372,"accession":"0000903423-19-000253","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000903423-19-000253","line_url":"/filing/0000903423-19-000253#line-2","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"VIKING GLOBAL PERFORMANCE LLC; Shabet Rose Sharon; HALVORSEN OLE ANDREAS; Ott David C.; Viking Long Fund Master Ltd.; Viking Long Fund GP LLC; Viking Global Equities Master Ltd.; Viking Global Equities LP; VGE III Portfolio Ltd.; Viking Global Equities II LP","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6706.0,"shares_display":"6,706","price_per_share":8.2107,"price_display":"8.21","price_state":"stated","total_value":55060.9542,"total_display":"55,060.95","shares_owned_after":22855056.0,"shares_owned_after_display":"22,855,056","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-18","filed_date":"2019-06-19","scope":"insider"},{"id":8665367,"accession":"0000903423-19-000253","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000903423-19-000253","line_url":"/filing/0000903423-19-000253#line-1","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"VIKING GLOBAL PERFORMANCE LLC; Shabet Rose Sharon; HALVORSEN OLE ANDREAS; Ott David C.; Viking Long Fund Master Ltd.; Viking Long Fund GP LLC; Viking Global Equities Master Ltd.; Viking Global Equities LP; VGE III Portfolio Ltd.; Viking Global Equities II LP","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6541.0,"shares_display":"6,541","price_per_share":8.5346,"price_display":"8.53","price_state":"stated","total_value":55824.8186,"total_display":"55,824.82","shares_owned_after":22848350.0,"shares_owned_after_display":"22,848,350","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-17","filed_date":"2019-06-19","scope":"insider"},{"id":7939233,"accession":"0000903423-19-000248","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000903423-19-000248","line_url":"/filing/0000903423-19-000248#line-3","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Viking Long Fund GP LLC; Shabet Rose Sharon; Ott David C.; VIKING GLOBAL PERFORMANCE LLC; Viking Global Equities Master Ltd.; Viking Long Fund Master Ltd.; Viking Global Equities II LP; VGE III Portfolio Ltd.; Viking Global Equities LP","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7144.0,"shares_display":"7,144","price_per_share":7.9107,"price_display":"7.91","price_state":"stated","total_value":56514.0408,"total_display":"56,514.04","shares_owned_after":22841809.0,"shares_owned_after_display":"22,841,809","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-14","filed_date":"2019-06-14","scope":"insider"},{"id":7939228,"accession":"0000903423-19-000248","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000903423-19-000248","line_url":"/filing/0000903423-19-000248#line-2","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Viking Long Fund GP LLC; Shabet Rose Sharon; Ott David C.; VIKING GLOBAL PERFORMANCE LLC; Viking Global Equities Master Ltd.; Viking Long Fund Master Ltd.; Viking Global Equities II LP; VGE III Portfolio Ltd.; Viking Global Equities LP","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7367.0,"shares_display":"7,367","price_per_share":7.9466,"price_display":"7.95","price_state":"stated","total_value":58542.6022,"total_display":"58,542.60","shares_owned_after":22834665.0,"shares_owned_after_display":"22,834,665","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-13","filed_date":"2019-06-14","scope":"insider"},{"id":7939224,"accession":"0000903423-19-000248","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000903423-19-000248","line_url":"/filing/0000903423-19-000248#line-1","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Viking Long Fund GP LLC; Shabet Rose Sharon; Ott David C.; VIKING GLOBAL PERFORMANCE LLC; Viking Global Equities Master Ltd.; Viking Long Fund Master Ltd.; Viking Global Equities II LP; VGE III Portfolio Ltd.; Viking Global Equities LP","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7500.0,"shares_display":"7,500","price_per_share":8.2992,"price_display":"8.30","price_state":"stated","total_value":62244.0,"total_display":"62,244.00","shares_owned_after":22827298.0,"shares_owned_after_display":"22,827,298","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-12","filed_date":"2019-06-14","scope":"insider"},{"id":7939221,"accession":"0000903423-19-000241","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000903423-19-000241","line_url":"/filing/0000903423-19-000241#line-3","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"Viking Global Equities Master Ltd.; VIKING GLOBAL PERFORMANCE LLC; Shabet Rose Sharon; Viking Long Fund Master Ltd.; Viking Long Fund GP LLC; Ott David C.; Viking Global Equities LP; VGE III Portfolio Ltd.; Viking Global Equities II LP; HALVORSEN OLE ANDREAS","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7189.0,"shares_display":"7,189","price_per_share":8.5817,"price_display":"8.58","price_state":"stated","total_value":61693.8413,"total_display":"61,693.84","shares_owned_after":22819798.0,"shares_owned_after_display":"22,819,798","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-11","filed_date":"2019-06-11","scope":"insider"},{"id":7939218,"accession":"0000903423-19-000241","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000903423-19-000241","line_url":"/filing/0000903423-19-000241#line-2","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"Viking Global Equities Master Ltd.; VIKING GLOBAL PERFORMANCE LLC; Shabet Rose Sharon; Viking Long Fund Master Ltd.; Viking Long Fund GP LLC; Ott David C.; Viking Global Equities LP; VGE III Portfolio Ltd.; Viking Global Equities II LP; HALVORSEN OLE ANDREAS","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7500.0,"shares_display":"7,500","price_per_share":8.3459,"price_display":"8.35","price_state":"stated","total_value":62594.25,"total_display":"62,594.25","shares_owned_after":22812609.0,"shares_owned_after_display":"22,812,609","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-10","filed_date":"2019-06-11","scope":"insider"},{"id":7939214,"accession":"0000903423-19-000241","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000903423-19-000241","line_url":"/filing/0000903423-19-000241#line-1","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"Viking Global Equities Master Ltd.; VIKING GLOBAL PERFORMANCE LLC; Shabet Rose Sharon; Viking Long Fund Master Ltd.; Viking Long Fund GP LLC; Ott David C.; Viking Global Equities LP; VGE III Portfolio Ltd.; Viking Global Equities II LP; HALVORSEN OLE ANDREAS","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6649.0,"shares_display":"6,649","price_per_share":7.965,"price_display":"7.96","price_state":"stated","total_value":52959.285,"total_display":"52,959.28","shares_owned_after":22805109.0,"shares_owned_after_display":"22,805,109","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-07","filed_date":"2019-06-11","scope":"insider"},{"id":8634700,"accession":"0000903423-19-000239","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000903423-19-000239","line_url":"/filing/0000903423-19-000239#line-3","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"Viking Long Fund Master Ltd.; Shabet Rose Sharon; Viking Long Fund GP LLC; Viking Global Equities II LP; VIKING GLOBAL PERFORMANCE LLC; Viking Global Equities Master Ltd.; VGE III Portfolio Ltd.; Viking Global Equities LP; HALVORSEN OLE ANDREAS; Ott David C.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7082.0,"shares_display":"7,082","price_per_share":7.9951,"price_display":"8.00","price_state":"stated","total_value":56621.2982,"total_display":"56,621.30","shares_owned_after":22798460.0,"shares_owned_after_display":"22,798,460","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-06","filed_date":"2019-06-06","scope":"insider"},{"id":8634697,"accession":"0000903423-19-000239","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000903423-19-000239","line_url":"/filing/0000903423-19-000239#line-2","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"Viking Long Fund Master Ltd.; Shabet Rose Sharon; Viking Long Fund GP LLC; Viking Global Equities II LP; VIKING GLOBAL PERFORMANCE LLC; Viking Global Equities Master Ltd.; VGE III Portfolio Ltd.; Viking Global Equities LP; HALVORSEN OLE ANDREAS; Ott David C.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6540.0,"shares_display":"6,540","price_per_share":8.015,"price_display":"8.02","price_state":"stated","total_value":52418.1,"total_display":"52,418.10","shares_owned_after":22791378.0,"shares_owned_after_display":"22,791,378","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-05","filed_date":"2019-06-06","scope":"insider"},{"id":8634691,"accession":"0000903423-19-000239","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000903423-19-000239","line_url":"/filing/0000903423-19-000239#line-1","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"Viking Long Fund Master Ltd.; Shabet Rose Sharon; Viking Long Fund GP LLC; Viking Global Equities II LP; VIKING GLOBAL PERFORMANCE LLC; Viking Global Equities Master Ltd.; VGE III Portfolio Ltd.; Viking Global Equities LP; HALVORSEN OLE ANDREAS; Ott David C.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7500.0,"shares_display":"7,500","price_per_share":7.5881,"price_display":"7.59","price_state":"stated","total_value":56910.75,"total_display":"56,910.75","shares_owned_after":22784838.0,"shares_owned_after_display":"22,784,838","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-04","filed_date":"2019-06-06","scope":"insider"},{"id":7967558,"accession":"0000903423-19-000244","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000903423-19-000244","line_url":"/filing/0000903423-19-000244#line-1","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"Viking Global Equities II LP; Viking Global Equities Master Ltd.; VIKING GLOBAL PERFORMANCE LLC; Viking Long Fund GP LLC; Ott David C.; Viking Long Fund Master Ltd.; HALVORSEN OLE ANDREAS; Viking Global Equities LP; VGE III Portfolio Ltd.; Shabet Rose Sharon","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, $0.000017727 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2424242.0,"shares_display":"2,424,242","price_per_share":8.25,"price_display":"8.25","price_state":"stated","total_value":19999996.5,"total_display":"19,999,996.50","shares_owned_after":40765599.0,"shares_owned_after_display":"40,765,599","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-04","filed_date":"2019-06-13","scope":"insider"},{"id":7939210,"accession":"0000903423-19-000237","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000903423-19-000237","line_url":"/filing/0000903423-19-000237#line-4","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"Viking Long Fund GP LLC; HALVORSEN OLE ANDREAS; VIKING GLOBAL PERFORMANCE LLC; Shabet Rose Sharon; Viking Long Fund Master Ltd.; VGE III Portfolio Ltd.; Viking Global Equities LP; Ott David C.; Viking Global Equities II LP; Viking Global Equities Master Ltd.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5424.0,"shares_display":"5,424","price_per_share":7.7092,"price_display":"7.71","price_state":"stated","total_value":41814.7008,"total_display":"41,814.70","shares_owned_after":22777338.0,"shares_owned_after_display":"22,777,338","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-03","filed_date":"2019-06-03","scope":"insider"},{"id":7939205,"accession":"0000903423-19-000237","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000903423-19-000237","line_url":"/filing/0000903423-19-000237#line-3","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"Viking Long Fund GP LLC; HALVORSEN OLE ANDREAS; VIKING GLOBAL PERFORMANCE LLC; Shabet Rose Sharon; Viking Long Fund Master Ltd.; VGE III Portfolio Ltd.; Viking Global Equities LP; Ott David C.; Viking Global Equities II LP; Viking Global Equities Master Ltd.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5071.0,"shares_display":"5,071","price_per_share":7.6991,"price_display":"7.70","price_state":"stated","total_value":39042.1361,"total_display":"39,042.14","shares_owned_after":22771914.0,"shares_owned_after_display":"22,771,914","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-31","filed_date":"2019-06-03","scope":"insider"},{"id":7939202,"accession":"0000903423-19-000237","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000903423-19-000237","line_url":"/filing/0000903423-19-000237#line-2","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"Viking Long Fund GP LLC; HALVORSEN OLE ANDREAS; VIKING GLOBAL PERFORMANCE LLC; Shabet Rose Sharon; Viking Long Fund Master Ltd.; VGE III Portfolio Ltd.; Viking Global Equities LP; Ott David C.; Viking Global Equities II LP; Viking Global Equities Master Ltd.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6951.0,"shares_display":"6,951","price_per_share":7.9726,"price_display":"7.97","price_state":"stated","total_value":55417.5426,"total_display":"55,417.54","shares_owned_after":22766543.0,"shares_owned_after_display":"22,766,543","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-30","filed_date":"2019-06-03","scope":"insider"},{"id":7939199,"accession":"0000903423-19-000237","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000903423-19-000237","line_url":"/filing/0000903423-19-000237#line-1","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"Viking Long Fund GP LLC; HALVORSEN OLE ANDREAS; VIKING GLOBAL PERFORMANCE LLC; Shabet Rose Sharon; Viking Long Fund Master Ltd.; VGE III Portfolio Ltd.; Viking Global Equities LP; Ott David C.; Viking Global Equities II LP; Viking Global Equities Master Ltd.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300.0,"shares_display":"300","price_per_share":8.9066,"price_display":"8.91","price_state":"stated","total_value":2671.98,"total_display":"2,671.98","shares_owned_after":22766843.0,"shares_owned_after_display":"22,766,843","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-30","filed_date":"2019-06-03","scope":"insider"},{"id":7967555,"accession":"0000903423-19-000233","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000903423-19-000233","line_url":"/filing/0000903423-19-000233#line-3","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"Viking Global Equities LP; VGE III Portfolio Ltd.; Viking Long Fund Master Ltd.; Shabet Rose Sharon; HALVORSEN OLE ANDREAS; Ott David C.; Viking Long Fund GP LLC; Viking Global Equities II LP; Viking Global Equities Master Ltd.; VIKING GLOBAL PERFORMANCE LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6882.0,"shares_display":"6,882","price_per_share":7.5535,"price_display":"7.55","price_state":"stated","total_value":51983.187,"total_display":"51,983.19","shares_owned_after":22759592.0,"shares_owned_after_display":"22,759,592","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-29","filed_date":"2019-05-29","scope":"insider"},{"id":7967553,"accession":"0000903423-19-000233","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000903423-19-000233","line_url":"/filing/0000903423-19-000233#line-2","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"Viking Global Equities LP; VGE III Portfolio Ltd.; Viking Long Fund Master Ltd.; Shabet Rose Sharon; HALVORSEN OLE ANDREAS; Ott David C.; Viking Long Fund GP LLC; Viking Global Equities II LP; Viking Global Equities Master Ltd.; VIKING GLOBAL PERFORMANCE LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3807.0,"shares_display":"3,807","price_per_share":7.6818,"price_display":"7.68","price_state":"stated","total_value":29244.6126,"total_display":"29,244.61","shares_owned_after":22752710.0,"shares_owned_after_display":"22,752,710","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-28","filed_date":"2019-05-29","scope":"insider"},{"id":7967548,"accession":"0000903423-19-000233","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000903423-19-000233","line_url":"/filing/0000903423-19-000233#line-1","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"Viking Global Equities LP; VGE III Portfolio Ltd.; Viking Long Fund Master Ltd.; Shabet Rose Sharon; HALVORSEN OLE ANDREAS; Ott David C.; Viking Long Fund GP LLC; Viking Global Equities II LP; Viking Global Equities Master Ltd.; VIKING GLOBAL PERFORMANCE LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3796.0,"shares_display":"3,796","price_per_share":7.7011,"price_display":"7.70","price_state":"stated","total_value":29233.3756,"total_display":"29,233.38","shares_owned_after":22748903.0,"shares_owned_after_display":"22,748,903","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-24","filed_date":"2019-05-29","scope":"insider"},{"id":8092042,"accession":"0000903423-19-000228","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000903423-19-000228","line_url":"/filing/0000903423-19-000228#line-3","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"Viking Long Fund Master Ltd.; HALVORSEN OLE ANDREAS; Shabet Rose Sharon; Viking Global Equities Master Ltd.; Viking Global Equities LP; Viking Global Equities II LP; VGE III Portfolio Ltd.; Viking Long Fund GP LLC; Ott David C.; VIKING GLOBAL PERFORMANCE LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4802.0,"shares_display":"4,802","price_per_share":7.7576,"price_display":"7.76","price_state":"stated","total_value":37251.9952,"total_display":"37,252.00","shares_owned_after":22745107.0,"shares_owned_after_display":"22,745,107","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-23","filed_date":"2019-05-23","scope":"insider"},{"id":8092040,"accession":"0000903423-19-000228","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000903423-19-000228","line_url":"/filing/0000903423-19-000228#line-2","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"Viking Long Fund Master Ltd.; HALVORSEN OLE ANDREAS; Shabet Rose Sharon; Viking Global Equities Master Ltd.; Viking Global Equities LP; Viking Global Equities II LP; VGE III Portfolio Ltd.; Viking Long Fund GP LLC; Ott David C.; VIKING GLOBAL PERFORMANCE LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5033.0,"shares_display":"5,033","price_per_share":8.0584,"price_display":"8.06","price_state":"stated","total_value":40557.9272,"total_display":"40,557.93","shares_owned_after":22740305.0,"shares_owned_after_display":"22,740,305","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-22","filed_date":"2019-05-23","scope":"insider"},{"id":8092038,"accession":"0000903423-19-000228","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000903423-19-000228","line_url":"/filing/0000903423-19-000228#line-1","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"Viking Long Fund Master Ltd.; HALVORSEN OLE ANDREAS; Shabet Rose Sharon; Viking Global Equities Master Ltd.; Viking Global Equities LP; Viking Global Equities II LP; VGE III Portfolio Ltd.; Viking Long Fund GP LLC; Ott David C.; VIKING GLOBAL PERFORMANCE LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9995.0,"shares_display":"9,995","price_per_share":8.5151,"price_display":"8.52","price_state":"stated","total_value":85108.4245,"total_display":"85,108.42","shares_owned_after":22735272.0,"shares_owned_after_display":"22,735,272","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-21","filed_date":"2019-05-23","scope":"insider"},{"id":8198311,"accession":"0000903423-19-000224","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000903423-19-000224","line_url":"/filing/0000903423-19-000224#line-4","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"VGE III Portfolio Ltd.; Shabet Rose Sharon; Viking Long Fund Master Ltd.; Viking Long Fund GP LLC; VIKING GLOBAL PERFORMANCE LLC; HALVORSEN OLE ANDREAS; Ott David C.; Viking Global Equities LP; Viking Global Equities Master Ltd.; Viking Global Equities II LP","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8285.0,"shares_display":"8,285","price_per_share":7.9833,"price_display":"7.98","price_state":"stated","total_value":66141.6405,"total_display":"66,141.64","shares_owned_after":null,"shares_owned_after_display":null,"ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-20","filed_date":"2019-05-20","scope":"insider"},{"id":8198306,"accession":"0000903423-19-000224","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000903423-19-000224","line_url":"/filing/0000903423-19-000224#line-3","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"VGE III Portfolio Ltd.; Shabet Rose Sharon; Viking Long Fund Master Ltd.; Viking Long Fund GP LLC; VIKING GLOBAL PERFORMANCE LLC; HALVORSEN OLE ANDREAS; Ott David C.; Viking Global Equities LP; Viking Global Equities Master Ltd.; Viking Global Equities II LP","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1715.0,"shares_display":"1,715","price_per_share":8.3867,"price_display":"8.39","price_state":"stated","total_value":14383.1905,"total_display":"14,383.19","shares_owned_after":null,"shares_owned_after_display":null,"ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-20","filed_date":"2019-05-20","scope":"insider"},{"id":8198304,"accession":"0000903423-19-000224","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000903423-19-000224","line_url":"/filing/0000903423-19-000224#line-2","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"VGE III Portfolio Ltd.; Shabet Rose Sharon; Viking Long Fund Master Ltd.; Viking Long Fund GP LLC; VIKING GLOBAL PERFORMANCE LLC; HALVORSEN OLE ANDREAS; Ott David C.; Viking Global Equities LP; Viking Global Equities Master Ltd.; Viking Global Equities II LP","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6200.0,"shares_display":"6,200","price_per_share":7.3615,"price_display":"7.36","price_state":"stated","total_value":45641.3,"total_display":"45,641.30","shares_owned_after":null,"shares_owned_after_display":null,"ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-17","filed_date":"2019-05-20","scope":"insider"},{"id":8198301,"accession":"0000903423-19-000224","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000903423-19-000224","line_url":"/filing/0000903423-19-000224#line-1","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"VGE III Portfolio Ltd.; Shabet Rose Sharon; Viking Long Fund Master Ltd.; Viking Long Fund GP LLC; VIKING GLOBAL PERFORMANCE LLC; HALVORSEN OLE ANDREAS; Ott David C.; Viking Global Equities LP; Viking Global Equities Master Ltd.; Viking Global Equities II LP","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5408.0,"shares_display":"5,408","price_per_share":6.7896,"price_display":"6.79","price_state":"stated","total_value":36718.1568,"total_display":"36,718.16","shares_owned_after":22709077.0,"shares_owned_after_display":"22,709,077","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-16","filed_date":"2019-05-20","scope":"insider"},{"id":7992421,"accession":"0000903423-19-000152","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000903423-19-000152","line_url":"/filing/0000903423-19-000152#line-1","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Axovant Sciences Ltd.","issuer_ticker":"AXON","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"Viking Global Equities Master Ltd.; Viking Global Equities LP; VGE III Portfolio Ltd.; Viking Long Fund GP LLC; VIKING GLOBAL PERFORMANCE LLC; HALVORSEN OLE ANDREAS; Viking Global Equities II LP; Viking Long Fund Master Ltd.; Ott David C.; Shabet Rose Sharon","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.00001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6666667.0,"shares_display":"6,666,667","price_per_share":1.5,"price_display":"1.50","price_state":"stated","total_value":10000000.5,"total_display":"10,000,000.50","shares_owned_after":105952381.0,"shares_owned_after_display":"105,952,381","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-03-18","filed_date":"2019-03-19","scope":"insider"},{"id":6138232,"accession":"0000903423-18-000641","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000903423-18-000641","line_url":"/filing/0000903423-18-000641#line-1","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Axovant Sciences Ltd.","issuer_ticker":"AXON","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Viking Global Equities LP; VIKING GLOBAL PERFORMANCE LLC; Viking Long Fund Master Ltd.; Viking Global Equities II LP; Viking Long Fund GP LLC; Shabet Rose Sharon; VGE III Portfolio Ltd.; Ott David C.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.00001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000000.0,"shares_display":"10,000,000","price_per_share":1.0,"price_display":"1.00","price_state":"stated","total_value":10000000.0,"total_display":"10,000,000.00","shares_owned_after":99285714.0,"shares_owned_after_display":"99,285,714","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-12-18","filed_date":"2018-12-20","scope":"insider"},{"id":6569567,"accession":"0000903423-18-000528","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000903423-18-000528","line_url":"/filing/0000903423-18-000528#line-1","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"Viking Long Fund GP LLC; VGE III Portfolio Ltd.; Viking Global Equities LP; Viking Global Equities II LP; VIKING GLOBAL PERFORMANCE LLC; Viking Long Fund Master Ltd.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, $0.000037453 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2678571.0,"shares_display":"2,678,571","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":37499994.0,"total_display":"37,499,994.00","shares_owned_after":22703669.0,"shares_owned_after_display":"22,703,669","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-10-01","filed_date":"2018-10-03","scope":"insider"},{"id":6745446,"accession":"0000903423-18-000325","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000903423-18-000325","line_url":"/filing/0000903423-18-000325#line-1","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Axovant Sciences Ltd.","issuer_ticker":"AXON","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"VGE III Portfolio Ltd.; Viking Global Equities LP; Viking Long Fund GP LLC; Viking Long Fund Master Ltd.; VIKING GLOBAL PERFORMANCE LLC; Viking Global Equities II LP","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, par value $0.00001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":14285714.0,"shares_display":"14,285,714","price_per_share":1.75,"price_display":"1.75","price_state":"stated","total_value":24999999.5,"total_display":"24,999,999.50","shares_owned_after":89285714.0,"shares_owned_after_display":"89,285,714","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-05","filed_date":"2018-06-07","scope":"insider"},{"id":6898626,"accession":"0000903423-18-000191","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000903423-18-000191","line_url":"/filing/0000903423-18-000191#line-1","is_derivative":false,"issuer_cik":"0001101785","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001101785","owner_cik":null,"owner_name":"VIKING GLOBAL PERFORMANCE LLC; Viking Long Fund Master Ltd.; Viking Long Fund GP LLC; Viking Global Equities LP; VGE III Portfolio Ltd.; Viking Global Equities II LP","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Shares, $0.000017727 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1110015.0,"shares_display":"1,110,015","price_per_share":20.27,"price_display":"20.27","price_state":"stated","total_value":22500004.05,"total_display":"22,500,004.05","shares_owned_after":38341357.0,"shares_owned_after_display":"38,341,357","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-04-02","filed_date":"2018-04-04","scope":"insider"},{"id":9206096,"accession":"0000903423-16-000809","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000903423-16-000809","line_url":"/filing/0000903423-16-000809#line-2","is_derivative":false,"issuer_cik":"0001621620","issuer_name":"Editas Medicine, Inc.","issuer_ticker":"EDIT","issuer_name_source":null,"issuer_url":"/issuer/0001621620","owner_cik":null,"owner_name":"VGE III Portfolio Ltd.; VIKING GLOBAL PERFORMANCE LLC; Viking Global Equities II LP; Viking Global Equities LP; Viking Long Fund GP LLC; Viking Long Fund Master Ltd.","owner_url":null,"role":"Other","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":20407.0,"shares_display":"20,407","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"shares_owned_after":2729808.0,"shares_owned_after_display":"2,729,808","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-02-08","filed_date":"2016-02-09","scope":"insider"},{"id":9206095,"accession":"0000903423-16-000809","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000903423-16-000809","line_url":"/filing/0000903423-16-000809#line-4","is_derivative":false,"issuer_cik":"0001621620","issuer_name":"Editas Medicine, Inc.","issuer_ticker":"EDIT","issuer_name_source":null,"issuer_url":"/issuer/0001621620","owner_cik":null,"owner_name":"VGE III Portfolio Ltd.; VIKING GLOBAL PERFORMANCE LLC; Viking Global Equities II LP; Viking Global Equities LP; Viking Long Fund GP LLC; Viking Long Fund Master Ltd.","owner_url":null,"role":"Other","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15072.0,"shares_display":"15,072","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"shares_owned_after":15072.0,"shares_owned_after_display":"15,072","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-02-08","filed_date":"2016-02-09","scope":"insider"},{"id":9206094,"accession":"0000903423-16-000809","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000903423-16-000809","line_url":"/filing/0000903423-16-000809#line-5","is_derivative":false,"issuer_cik":"0001621620","issuer_name":"Editas Medicine, Inc.","issuer_ticker":"EDIT","issuer_name_source":null,"issuer_url":"/issuer/0001621620","owner_cik":null,"owner_name":"VGE III Portfolio Ltd.; VIKING GLOBAL PERFORMANCE LLC; Viking Global Equities II LP; Viking Global Equities LP; Viking Long Fund GP LLC; Viking Long Fund Master Ltd.","owner_url":null,"role":"Other","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":481567.0,"shares_display":"481,567","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"shares_owned_after":481567.0,"shares_owned_after_display":"481,567","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-02-08","filed_date":"2016-02-09","scope":"insider"},{"id":9206093,"accession":"0000903423-16-000809","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000903423-16-000809","line_url":"/filing/0000903423-16-000809#line-6","is_derivative":false,"issuer_cik":"0001621620","issuer_name":"Editas Medicine, Inc.","issuer_ticker":"EDIT","issuer_name_source":null,"issuer_url":"/issuer/0001621620","owner_cik":null,"owner_name":"VGE III Portfolio Ltd.; VIKING GLOBAL PERFORMANCE LLC; Viking Global Equities II LP; Viking Global Equities LP; Viking Long Fund GP LLC; Viking Long Fund Master Ltd.","owner_url":null,"role":"Other","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":261447.0,"shares_display":"261,447","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"shares_owned_after":261447.0,"shares_owned_after_display":"261,447","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-02-08","filed_date":"2016-02-09","scope":"insider"}],"next_cursor":"2015-02-08|9206093","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001796209","name":"APi Group Corp","url":"/issuer/0001796209","role":"Ten percent owner","n_filings":3,"first_seen":"2024-01-04","last_seen":"2024-06-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001635088","name":"Roivant Sciences Ltd.","url":"/issuer/0001635088","role":"Ten percent owner","n_filings":1,"first_seen":"2023-06-26","last_seen":"2023-06-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001478320","name":"Adaptive Biotechnologies Corp","url":"/issuer/0001478320","role":"Ten percent owner","n_filings":3,"first_seen":"2020-01-30","last_seen":"2020-12-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001740547","name":"Urovant Sciences Ltd.","url":"/issuer/0001740547","role":"Ten percent owner","n_filings":9,"first_seen":"2018-10-03","last_seen":"2019-06-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001679082","name":"Myovant Sciences Ltd.","url":"/issuer/0001679082","role":"Ten percent owner","n_filings":2,"first_seen":"2018-04-04","last_seen":"2019-06-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001636050","name":"Axovant Sciences Ltd.","url":"/issuer/0001636050","role":"Ten percent owner","n_filings":3,"first_seen":"2018-06-07","last_seen":"2019-03-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001650664","name":"Editas Medicine, Inc.","url":"/issuer/0001650664","role":"Ten percent owner, Other","n_filings":2,"first_seen":"2016-02-08","last_seen":"2016-02-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001616707","name":"Wayfair Inc.","url":"/issuer/0001616707","role":"Ten percent owner","n_filings":1,"first_seen":"2014-10-06","last_seen":"2014-10-06"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001413378","retrieved_at":"2026-08-21T13:39:46+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}